CD8A and neoplasm: This was confirmed in a pre-clinical study, which suggested that the application of anti-VEGF-A antibody (sunitinib) in CT26 tumor-bearing mice increases the infiltration of cytotoxic tumor-infiltrating lymphocytes (TIL) and decreases PD-1 expression in CD8+T cells (32).